# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Robbie Marcus initiates coverage on GE HealthCare Techs (NASDAQ:GEHC) with a Neutral rating and announces ...
Published in Anesthesia and Analgesia, results from the multi-site trial evaluating End-tidal Control software provide compelli...
Project aims to increase access of advanced imaging techniques for clinicians to help drive improved diagnosis and management o...
Jim Cramer recommends buying Merck (MRK) due to faith in CEO Robert Davis. He advises against Teladoc (TDOC) due to Cathie Wood...
Stifel analyst Rick Wise initiates coverage on GE HealthCare Techs (NASDAQ:GEHC) with a Buy rating and announces Price Targe...
GE Healthcare reported Q2 sales of $4.84 billion. Net income rose to $428 million, and adjusted EPS beat estimates at $1.00. De...